Zhiwu Tan

Dr. Zhiwu Tan

Department of Life Sciences, The Hong Kong Polytechnic University, Hong Kong, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ZTZhiwu Tan
Zhiwu Tan
JZJingying Zhou
Jingying Zhou
Allen Ka Loon CheungAllen Ka Loon Cheung
Allen Ka Loon Cheung
ZYZhe Yu
Zhe Yu
KCKa-Wai Cheung
Ka-Wai Cheung
ZCZhiwei Chen
Zhiwei Chen
Eradicating malignant tumors by vaccine-elicited host immunity remains a major medical challenge. To date, correlates of immune protection remain unknown for malignant mesothelioma. In this study, we demonstrated that antigen-specific CD8+ T-cell immune response correlates with the elimination of malignant mesothelioma by a model PD-1–based DNA vaccine. Unlike the nonprotective tumor antigen WT1-based DNA vaccines, the model vaccine showed complete and long-lasting protection against lethal mesothelioma challenge in immunocompetent BALB/c mice. Furthermore, it remained highly immunogenic in tumor-bearing animals and led to therapeutic cure of preexisting mesothelioma. T-cell depletion and adoptive transfer experiments revealed that vaccine-elicited CD8+ T cells conferred to the protective efficacy in a dose-dependent way. Also, these CD8+ T cells functioned by releasing inflammatory IFNγ and TNFα in the vicinity of target cells as well as by initiating TRAIL-directed tumor cell apoptosis. Importantly, repeated DNA vaccinations, a major advantage over live-vectored vaccines with issues of preexisting immunity, achieve an active functional state, not only preventing the rise of exhausted PD-1+ and Tim-3+ CD8+ T cells but also suppressing tumor-induced myeloid-derived suppressive cells and Treg cells, with the frequency of antigen-specific CD8+ T cells inversely correlating with tumor mass. Our results provide new insights into quantitative and qualitative requirements of vaccine-elicited functional CD8+ T cells in cancer prevention and immunotherapy. Cancer Res; 74(21); 6010–21. ©2014 AACR.

11 January 2022 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
WWWai Ki Wong
Wai Ki Wong
BYBohan Yin
Bohan Yin
CLChing Ying Katherine Lam
Ching Ying Katherine Lam
YHYingying Huang
Yingying Huang
JYJiaxiang Yan
Jiaxiang Yan
Siu Hong Dexter WongSiu Hong Dexter Wong
Siu Hong Dexter Wong
Effective immunotherapy treats cancers by eradicating tumourigenic cells by activated tumour antigen-specific and bystander CD8+ T-cells. However, T-cells can gradually lose cytotoxicity in the tumour microenvironment, known as exhaustion. Recently, DNA methylation, histone modification, and chromatin architecture have provided novel insights into epigenetic regulations of T-cell differentiation/exhaustion, thereby controlling the translational potential of the T-cells. Thus, developing strategies to govern epigenetic switches of T-cells dynamically is critical to maintaining the effector function of antigen-specific T-cells. In this mini-review, we 1) describe the correlation between epigenetic states and T cell phenotypes; 2) discuss the enzymatic factors and intracellular/extracellular microRNA imprinting T-cell epigenomes that drive T-cell exhaustion; 3) highlight recent advances in epigenetic interventions to rescue CD8+ T-cell functions from exhaustion. Finally, we express our perspective that regulating the interplay between epigenetic changes and transcriptional programs provides translational implications of current immunotherapy for cancer treatments.

3 April 2026 in Cancer Research
Verified
Journal Article
Closed access
ZTZhiwu Tan
Zhiwu Tan
MCMei Sum Chiu
Mei Sum Chiu
HYHelen Xinyue Yu
Helen Xinyue Yu
XCXiaoxiao Chang
Xiaoxiao Chang
ZCZhiwei Chen
Zhiwei Chen
TWIST1, a basic helix-loop-helix transcription factor, is overexpressed in a variety of tumors such as melanoma, breast, colon cancer and mesothelioma, and associated with tumorigenesis and metastasis. We have previously shown that full-length TWIST1 vaccine elicited cytotoxic T lymphocytes (CTLs) that recognized TWIST1-expressing tumors and conferred protection against tumor challenge in the form of DNA vaccine and adeno-associated viral vector system, highlighting TWIST1 as a promising target for cancer immunotherapy. In this study, we sought to apply optimization approach on the TWIST1-based vaccine platform in order to enhance T cell immunity and reduce potential toxicity. We developed a novel soluble PD-1 (sPD1)-based DNA vaccine encoding a truncated version of TWIST1 (sPD1-TruncT1) that includes major T cell epitopes found in both human and mouse proteins. The immunogenicity and antitumor efficacy of the vaccine were evaluated and compared in parallel to full-length TWIST1 vaccine in two murine models of TWIST1-expressing tumors. By doing epitope mapping, we identified immunodominant T cell epitopes within the TWIST1 antigen, showing that majority of T cells recognized a C-terminal conserved region. sPD1-based DNA vaccine encoding epitopes of this conserved region, via in vivo electroporation (EP), elicited more robust TWIST1-specific T cell responses compared to full-length TWIST1 vaccine. Furthermore, these TWIST1-specific T cells were polyfunctional because they produced multiple effector cytokines when encountering TWIST1-expressing tumors. In addition, immunotherapy with the sPD1-TruncT1 vaccine showed a notable enhancement in antitumor efficacy in both preventive and therapeutic scenarios. With the widespread expression of TWIST1 in different cancer types, truncated TWIST1 vaccination has high potential for cancer immunotherapy and warrants investigation in human clinical trials to evaluate its applications as a vaccine for patients with WT1-expressing cancers. Citation Format: Zhiwu Tan, Mei Sum Chiu, Helen Xinyue Yu, Xiaoxiao Chang, Zhiwei Chen. Enhanced cancer immunotherapy via sPD1-based DNA vaccination targeting epitope-focused TWIST1 antigen [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4379.

1 November 2025 in The Journal of Immunology
Verified
Journal Article
Closed access
HXHaoran Xu
Haoran Xu
MYMing Yue
Ming Yue
RZRunhong Zhou
Runhong Zhou
PWPui Wang
Pui Wang
ZTZhiwu Tan
Zhiwu Tan
ZCZhiwei Chen
Zhiwei Chen
Description: : Memory T cells play a key role in immune protection against cancer. Vaccine-induced tissue-resident memory T (TRM) cells in the lung have been shown to protect against lung metastasis. Identifying the source of lung TRM cells can help to improve strategies, preventing tumor metastasis. Here, we found that a prime-boost vaccination approach using intramuscular DNA vaccine priming, followed by intranasal live-attenuated influenza vectored vaccine (LAIV) boosting induced higher frequencies of lung CD8+ TRM cells compared with other vaccination regimens. Vaccine-induced lung CD8+ TRM cells, but not circulating memory T cells, conferred significant protection against metastatic melanoma and mesothelioma. Central memory T (TCM) cells induced by the DNA vaccination were major precursors of lung TRM cells established after the intranasal LAIV boost. Single-cell RNA sequencing analysis indicated that transcri! ptional reprogramming of TCM cells for differentiation into TRM cells in the lungs started as early as day 2 post the LAIV boost. Intranasal LAIV altered the mucosal microenvironment to recruit TCM cells via CXCR3- dependent chemotaxis and induced CD8+ TRM-associated transcriptional programs. These results identified TCM cells as the source of vaccine-induced CD8+ TRM cells that protect against lung metastasis. Funding Sources: Supported by RGC TRS (T11-706/18-N, T12-703/23-N, and T11-702/24-N to Z. Chen) and Collaborative Research Fund (C7156-20G), RGC GRF (17117422), Health@InnoHK (Center for Virology, Vaccinology and Therapeutics) Topic Categories: Mucosal and Regional Immunology (MUC)